CLINICAL TRIALS PROFILE FOR CHORIOGONADOTROPIN ALFA
✉ Email this page to a colleague
All Clinical Trials for choriogonadotropin alfa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01406600 ↗ | Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles | Unknown status | Seoul National University Hospital | N/A | 2011-09-01 | Choriogonadotropin alfa (Ovidrel®) is a recombinant hCG (rhCG) preparation derived from genetically engineered Chinese hamster ovary cells, which is widely used for final oocyte maturation triggering in assisted reproductive technology (ART).Recombinant hCG has been investigated about its safety and efficacy comparing with urinary hCG, but still the optimal dose of rhCG is questionable. From former studies, there only have been proven that high dose of hCG can make ovarian hyperstimulation syndrome (OHSS) in usual condition. On the other hand, we hypothesize that high dose of hCG may improve oocyte maturity in poor responders who cannot easily provoke OHSS. Hence, this study will assess the comparative efficacy and safety of 250mcg and 500mcg of rhCG in ART treatment cycle. |
| NCT02677259 ↗ | Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles | Unknown status | One Fertility | Phase 2 | 2016-05-01 | Optimizing in vitro fertilization (IVF) success is more important than ever, in light of new public funding of IVF in Ontario, Canada. In patients undergoing IVF using gonadotropin-releasing hormone (GnRH) analogues, the luteal phase appears to be compromised, which may be a result of controlled-ovarian hyperstimulation, significant fluctuations in hormone levels, the impact of the oocyte retrieval process, or direct compromise of the corpus luteum. Progesterone support is definitely necessary during the luteal phase to facilitate implantation but whether estrogen supplementation is also needed remains unclear. The present study aims to determine whether estradiol support during the luteal phase improves clinical pregnancy rate in patients undergoing IVF. |
| NCT02992808 ↗ | Androgenic Profile Following Controlled Ovarian Stimulation | Unknown status | Sheba Medical Center | Phase 4 | 2016-12-01 | In this study the investigators will try to discover whether there is a difference for any of the stimulation preparations - recombinant FSH + recombinant LH (pergoveris & luveris) vs. human menopausal gonadotropin (menopur) during GnRH-antagonist cycles in the meaning of androgenic hormones profile. The study question is whether using recombinant LH will result in different follicular hormonal milieu, serum endocrine profile or IVF outcomes than using highly purified urinary gonadotropins with hCG mimicking LH activity. |
| NCT05450900 ↗ | Can Biotin Supplementation be Used to Mask hCG Abuse? | Recruiting | Sports Medicine Research and Testing Laboratory | Early Phase 1 | 2022-07-05 | This sponsor is an anti-doping laboratory tasked with testing athlete samples for prohibited substances by the World Anti-Doping Agency and other agencies. This study is intended to measure: 1. Urinary/serum hCG (human chorionic gonadotropin) and urinary biotin concentrations in both treatment groups before, during, and after hCG intervention using standard immunoassay methods 2. To monitor hCG in both treatment groups before and after diafiltration of urine samples prior to analysis 3. To compare urinary and serum detectability (detection window, sensitivity) of hCG abuse in the hCG-only group compared to the hCG + biotin group |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for choriogonadotropin alfa
Condition Name
Clinical Trial Locations for choriogonadotropin alfa
Trials by Country
Clinical Trial Progress for choriogonadotropin alfa
Clinical Trial Phase
Clinical Trial Sponsors for choriogonadotropin alfa
Sponsor Name
